Bevacizumab-induced regression of anaplastic meningioma

Annals of Oncology

Volumn 21, Issue 12, 2010, Pages 2445-2446

  Puchner, M J A ^a   Hans, V H ^b   Harati, A ^a   Lohmann, F ^a   Glas, M ^c   Herrlinger, U ^c  

^a Knappschaftskrankenhaus Recklinghausen   (Germany)

^b EVANGELISCHES KRANKENHAUS   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; ANAPLASTIC MENINGIOMA; APHASIA; BRAIN SURGERY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LETTER; MENINGIOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOSOMATIC DISORDER; TREATMENT DURATION; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 78649457791     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq634     Document Type: Letter

References (5)

1. Modha A, Gutin PH. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 2005; 57: 538-550.
2. Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 1996; 84: 733-736.
3. Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 2010; 96: 211-217.
4. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 2007; 69: 969-973.
5. Lamszus K, Lengler U, Schmidt NO, et al. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 2000; 46: 938-947.